A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Clinical trial NCT03611868 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03611868
Sponsor: Ascentage Pharma Group Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Unresectable or Metastatic Melanoma or Advanced Solid Tumors Melanoma Uveal Melanoma P53 Mutation MDM2 Gene Mutation Cutaneous Melanoma Mucosal Melanoma Malignant Peripheral Nerve Sheath Tumors (MPNST)

Start date: 2018-08-29
Primary completion: 2025-12-30
Enrollment: 230

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.